101 related articles for article (PubMed ID: 20032381)
1. ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.
Woessner R; Tunquist B; Lemieux C; Chlipala E; Jackinsky S; Dewolf W; Voegtli W; Cox A; Rana S; Lee P; Walker D
Anticancer Res; 2009 Nov; 29(11):4373-80. PubMed ID: 20032381
[TBL] [Abstract][Full Text] [Related]
2. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.
Tunquist BJ; Woessner RD; Walker DH
Mol Cancer Ther; 2010 Jul; 9(7):2046-56. PubMed ID: 20571074
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.
Carter BZ; Mak DH; Woessner R; Gross S; Schober WD; Estrov Z; Kantarjian H; Andreeff M
Leukemia; 2009 Oct; 23(10):1755-62. PubMed ID: 19458629
[TBL] [Abstract][Full Text] [Related]
4. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
Ye XS; Fan L; Van Horn RD; Nakai R; Ohta Y; Akinaga S; Murakata C; Yamashita Y; Yin T; Credille KM; Donoho GP; Merzoug FF; Li H; Aggarwal A; Blanchard K; Westin EH
Mol Cancer Ther; 2015 Nov; 14(11):2463-72. PubMed ID: 26304237
[TBL] [Abstract][Full Text] [Related]
5. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
[TBL] [Abstract][Full Text] [Related]
6. SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.
Basso AD; Liu M; Gray K; Tevar S; Lee S; Liang L; Ponery A; Smith EB; Monsma FJ; Yu T; Zhang Y; Kerekes AD; Esposite S; Xiao Y; Tagat JR; Hicklin DJ; Kirschmeier P
Cancer Chemother Pharmacol; 2011 Oct; 68(4):923-33. PubMed ID: 21298383
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
Mansoor UF; Angeles AR; Dai C; Yang L; Vitharana D; Basso AD; Gray K; Tang H; Liu M; Liang L; Allbritton O; Siddiqui MA
Bioorg Med Chem; 2015 May; 23(10):2424-34. PubMed ID: 25868746
[TBL] [Abstract][Full Text] [Related]
8. SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics.
Basso AD; Liu M; Dai C; Gray K; Nale L; Tevar S; Lee S; Liang L; Ponery A; Yaremko B; Smith E; Tang H; Sheth PR; Siddiqui MA; Hicklin DJ; Kirschmeier P
Mol Cancer Ther; 2010 Nov; 9(11):2993-3002. PubMed ID: 20978164
[TBL] [Abstract][Full Text] [Related]
9. Novel ATP-competitive kinesin spindle protein inhibitors.
Parrish CA; Adams ND; Auger KR; Burgess JL; Carson JD; Chaudhari AM; Copeland RA; Diamond MA; Donatelli CA; Duffy KJ; Faucette LF; Finer JT; Huffman WF; Hugger ED; Jackson JR; Knight SD; Luo L; Moore ML; Newlander KA; Ridgers LH; Sakowicz R; Shaw AN; Sung CM; Sutton D; Wood KW; Zhang SY; Zimmerman MN; Dhanak D
J Med Chem; 2007 Oct; 50(20):4939-52. PubMed ID: 17725339
[TBL] [Abstract][Full Text] [Related]
10. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action.
Lee MS; Johansen L; Zhang Y; Wilson A; Keegan M; Avery W; Elliott P; Borisy AA; Keith CT
Cancer Res; 2007 Dec; 67(23):11359-67. PubMed ID: 18056463
[TBL] [Abstract][Full Text] [Related]
11. KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.
Kim KH; Xie Y; Tytler EM; Woessner R; Mor G; Alvero AB
J Transl Med; 2009 Jul; 7():63. PubMed ID: 19619321
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
Khoury HJ; Garcia-Manero G; Borthakur G; Kadia T; Foudray MC; Arellano M; Langston A; Bethelmie-Bryan B; Rush S; Litwiler K; Karan S; Simmons H; Marcus AI; Ptaszynski M; Kantarjian H
Cancer; 2012 Jul; 118(14):3556-64. PubMed ID: 22139909
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
14. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
Cox CD; Garbaccio RM
Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Manfredi MG; Ecsedy JA; Chakravarty A; Silverman L; Zhang M; Hoar KM; Stroud SG; Chen W; Shinde V; Huck JJ; Wysong DR; Janowick DA; Hyer ML; Leroy PJ; Gershman RE; Silva MD; Germanos MS; Bolen JB; Claiborne CF; Sells TB
Clin Cancer Res; 2011 Dec; 17(24):7614-24. PubMed ID: 22016509
[TBL] [Abstract][Full Text] [Related]
17. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.
Cox CD; Breslin MJ; Mariano BJ; Coleman PJ; Buser CA; Walsh ES; Hamilton K; Huber HE; Kohl NE; Torrent M; Yan Y; Kuo LC; Hartman GD
Bioorg Med Chem Lett; 2005 Apr; 15(8):2041-5. PubMed ID: 15808464
[TBL] [Abstract][Full Text] [Related]
18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways.
Vijapurkar U; Wang W; Herbst R
Cancer Res; 2007 Jan; 67(1):237-45. PubMed ID: 17210704
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
